Journal article
Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017-2019)
International journal of infectious diseases, Vol.107, pp.92-100
04/20/2021
DOI: 10.1016/j.ijid.2021.04.014
PMID: 33857605
Abstract
The antimicrobial activity of tedizolid and comparators was evaluated against a large worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae isolates recovered from patients with pneumonia.
Clinical isolates were collected from patients in 96 medical centres in the Asia-Pacific region, Europe, Latin America and the USA between 2017 and 2019, and tested for susceptibility by reference broth microdilution.
The most active agents against S. aureus (n = 4667) were tedizolid (100.0% susceptible), linezolid (100.0% susceptible), ceftaroline (96.2% susceptible) and vancomycin (100.0% susceptible), but only tedizolid, linezolid and vancomycin retained activity against >95% of meticillin-resistant S. aureus isolates from all regions. In general, linezolid, ceftriaxone, ceftaroline, levofloxacin, penicillin and vancomycin showed susceptibility rates >95% against S. pneumoniae (n = 3008). However, only linezolid, ceftaroline, levofloxacin and vancomycin remained active (>95% susceptibility) against isolates displaying penicillin-non-susceptible or multidrug-resistant phenotypes. Penicillin-non-susceptible S. pneumoniae isolates were recovered less frequently from patients aged <5 years compared with other age groups.
The in-vitro data presented here confirm the high potency of tedizolid against S. aureus and S. pneumoniae causing pneumonia worldwide. There is a need for further clinical evaluations of tedizolid for treating pneumonia caused by these pathogens.
Details
- Title: Subtitle
- Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017-2019)
- Creators
- Cecilia G Carvalhaes - JMI LaboratoriesHelio S Sader - JMI LaboratoriesPaul R Rhomberg - JMI LaboratoriesRodrigo E Mendes - JMI Laboratories
- Resource Type
- Journal article
- Publication Details
- International journal of infectious diseases, Vol.107, pp.92-100
- DOI
- 10.1016/j.ijid.2021.04.014
- PMID
- 33857605
- ISSN
- 1201-9712
- eISSN
- 1878-3511
- Grant note
- DOI: 10.13039/100009947, name: Merck Sharp and Dohme
- Language
- English
- Date published
- 04/20/2021
- Academic Unit
- Pathology
- Record Identifier
- 9984185277202771
Metrics
8 Record Views